UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its Charter) Delaware 47-4839948 (State or other jurisdict ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2020 Earnings Conference Call November 9, 2020 8:00 AM ET Company Participants Robert Gould - CEO, President & Director Diego Cadavid - SVP of Clinical Development Owen Wallace - Chief Scientific Officer Bryan Stuart - Chief Operating Officer Christi Waarich - Director, Corporate Communications & IR Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Leerink Kostas Biliouris - Morgan Stanley Operator Good morning, and welcome to the Ful ...

For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other j ...

Fulcrum | --- | --- | --- | --- | |-------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease September 2020 | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development statu ...

Fulcrum | --- | --- | --- | --- | --- | --- | |---------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fulcrum Q2 2020 Conference Call | | | | | | | August 11, 2020 | | | | | | | | | | | | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regard ...

Fulcrum Therapeutics Inc. (NASDAQ:FULC) Q2 2020 Results Conference Call August 11, 2020 8:00 AM ET Company Participants Christi Waarich - Director, Corporate Communications & IR Robert Gould - CEO, President & Director Diego Cadavid - SVP of Clinical Development Owen Wallace - Chief Scientific Officer Bryan Stuart - Chief Operating Officer Conference Call Participants Joseph Schwartz - SVB Leerink Dae Gon Ha - BTIG Tazeen Ahmad - Bank of America Ted Tenthoff - Piper Sandler Matthew Harrison - Morgan Stanl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other jurisd ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2020 Earnings Conference Call May 13, 2020 8:00 AM ET Company Participants Christi Waarich - Director of Investor Relations and Corporate Communications Robert Gould - President and Chief Executive Officer Owen Wallace - Chief Scientific Officer Bryan Stuart - Chief Operating Officer Diego Cadavid - Senior Vice President of Clinical Development Conference Call Participants Joseph Schwartz - SVB Leerink Tazeen Ahmad - Bank of America Operator Good morning and welco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (617) 651-8851 Securities registered pursuant to S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its Charter) Delaware 47-4839948 (State or other jurisdict ...